Argonaut Therapeutics Limited

Epigenetic drugs for the treatment, diagnosis, detection and prevention of cancer; epigenetic drugs targeting arginine methylation in cancer; pharmaceutical preparations in the nature of inhibitors of arginine methylation for the treatment of cancer; pharmaceutical preparations in the nature of inhibitors of protein arginine methyl-transferase (PRMT) for the treatment of cancer; cancer treatment vaccines; therapeutic vaccines for treating cancer; cancer therapy subsection vaccines; pharmaceutical compounds for the treatment, diagnosis, detection and prevention of cancer; pharmaceutical products, preparations and substances for the treatment, diagnosis, detection and prevention of cancer; biological preparations and substances for the treatment, diagnosis, detection and prevention of cancer

Epigenetic drugs for the treatment, diagnosis, detection and prevention of cancer; epigenetic drugs targeting arginine methylation in cancer; pharmaceutical preparations in the nature of inhibitors of arginine methylation for the treatment of cancer; pharmaceutical preparations in the nature of inhibitors of protein arginine methyl-transferase (PRMT) for the treatment of cancer; cancer treatment vaccines; therapeutic vaccines for treating cancer; cancer therapy subsection vaccines; pharmaceutical compounds for the treatment, diagnosis, detection and prevention of cancer; pharmaceutical products, preparations and substances for the treatment, diagnosis, detection and prevention of cancer; biological preparations and substances for the treatment, diagnosis, detection and prevention of cancer | Research and development services in the pharmaceutical and biotechnology fields; medical research and development services in the pharmaceutical and biotechnology fields; scientific research and development services; pharmaceutical research and development services; research and development in the field of epigenetic drugs for the treatment, diagnosis, detection and prevention of cancer; research and development in the field of epigenetic drugs targeting arginine methylation in cancer; research and development in the field of inhibitors of arginine methylation for the treatment of cancer; research and development in the field of inhibitors of protein arginine methyl-transferase (PRMT) for the treatment of cancer; research and development in the field of cancer treatment vaccines, therapeutic vaccines for treating cancer and cancer therapy subsection vaccines; research and development in the field of compounds for the treatment, diagnosis, detection and prevention of cancer; research and development in the field of pharmaceutical products, preparations and substances for the treatment, diagnosis, detection and prevention of cancer; research and development in the field of biological preparations and substances for the treatment, diagnosis, detection and prevention of cancer; consultancy, advisory and information services relating to and connected with the aforementioned services

Class 005: Epigenetic drugs for the treatment, diagnosis, detection and prevention of cancer; epigenetic drugs targeting arginine methylation in cancer; pharmaceutical preparations in the nature of inhibitors of arginine methylation for the treatment of cancer; pharmaceutical preparations in the nature of inhibitors of protein arginine methyl-transferase (PRMT) for the treatment of cancer; cancer treatment vaccines; therapeutic vaccines for treating cancer; cancer therapy subsection vaccines; pharmaceutical compounds for the treatment, diagnosis, detection and prevention of cancer; pharmaceutical products, preparations and substances for the treatment, diagnosis, detection and prevention of cancer; biological preparations and substances for the treatment, diagnosis, detection and prevention of cancer; Class 042: Research and development services in the pharmaceutical and biotechnology fields; medical research and development services in the pharmaceutical and biotechnology fields; scientific research and development services; pharmaceutical research and development services; research and development in the field of epigenetic drugs for the treatment, diagnosis, detection and prevention of cancer; research and development in the field of epigenetic drugs targeting arginine methylation in cancer; research and development in the field of inhibitors of arginine methylation for the treatment of cancer; research and development in the field of inhibitors of protein arginine methyl-transferase (PRMT) for the treatment of cancer; research and development in the field of cancer treatment vaccines, therapeutic vaccines for treating cancer and cancer therapy subsection vaccines; research and development in the field of compounds for the treatment, diagnosis, detection and prevention of cancer; research and development in the field of pharmaceutical products, preparations and substances for the treatment, diagnosis, detection and prevention of cancer; research and development in the field of biological preparations and substances for the treatment, diagnosis, detection and prevention of cancer; consultancy, advisory and information services relating to and connected with the aforementioned services

Class 005: Epigenetic drugs for the treatment, diagnosis, detection and prevention of cancer; epigenetic drugs targeting arginine methylation in cancer; pharmaceutical preparations in the nature of inhibitors of arginine methylation for the treatment of cancer; pharmaceutical preparations in the nature of inhibitors of protein arginine methyl-transferase (PRMT) for the treatment of cancer; cancer treatment vaccines; therapeutic vaccines for treating cancer; cancer therapy subsection vaccines; pharmaceutical compounds for the treatment, diagnosis, detection and prevention of cancer; pharmaceutical products, preparations and substances for the treatment, diagnosis, detection and prevention of cancer; biological preparations and substances for the treatment, diagnosis, detection and prevention of cancer; Class 042: Research and development services in the pharmaceutical and biotechnology fields; medical research and development services in the pharmaceutical and biotechnology fields; scientific research and development services; pharmaceutical research and development services; research and development in the field of epigenetic drugs for the treatment, diagnosis, detection and prevention of cancer; research and development in the field of epigenetic drugs targeting arginine methylation in cancer; research and development in the field of inhibitors of arginine methylation for the treatment of cancer; research and development in the field of inhibitors of protein arginine methyl-transferase (PRMT) for the treatment of cancer; research and development in the field of cancer treatment vaccines, therapeutic vaccines for treating cancer and cancer therapy subsection vaccines; research and development in the field of compounds for the treatment, diagnosis, detection and prevention of cancer; research and development in the field of pharmaceutical products, preparations and substances for the treatment, diagnosis, detection and prevention of cancer; research and development in the field of biological preparations and substances for the treatment, diagnosis, detection and prevention of cancer; consultancy, advisory and information services relating to and connected with the aforementioned services